Carisma lets go of 37% of staff, CAR-M candidate to stretch cash runway

Phase 1Cell TherapyImmunotherapyGene TherapyIND
Carisma lets go of 37% of staff, CAR-M candidate to stretch cash runway
Preview
Source: FierceBiotech
Its prioritized programs demonstrate the greatest overall potential and near-term milestones, Carisma CEO Steven Kelly said.
Carisma Therapeutics plans to let go of 37% of staffers and drop one of two clinical assets in an effort to fuel the immunotherapy-focused biotech into the third quarter of 2025.
The update, shared this morning, sent the company’s stock down 9%, slipping from $2.27 per share at market open to $2.08 as of 12:30 p.m. ET today.
Since increasing its head count via a reverse merger with Sesen Bio in March 2023, Carisma's personnel costs have climbed. Now, the biotech is trimming the team and implementing a revised operating plan designed to cut general and administrative expenses, according to the April 1 release.
Part of the restructure includes stopping development of CT-0508, a chimeric antigen receptor macrophage (CAR-macrophage) being studied among patients with HER2 overexpressing solid tumors in an open-label phase 1 trial. Last fall, the biotech shared early data from 14 patients that found the investigational treatment was well tolerated, remodeled the tumor microenvironment and induced anti-tumor T-cell immunity in certain patients.
Despite this, Carisma sees more promise in its chimeric antigen receptor-monocyte (CAR-monocyte) approach and plans to stop recruiting new patients for the CT-0508 trial. The biotech is also ending a sub-study that evaluated CT-0508 in combination with Keytruda.
Carisma will instead focus on CT-0525, an ex vivo gene-modified autologous CAR-monocyte cell therapy designed to treat solid tumors that overexpress HER2. An open-label phase 1 clinical trial assessing the candidate launched at the beginning of this year, according to ClinicalTrials.gov.
The company expects to dose the first patient in the CT-0525 study in the second quarter and plans to report initial data by the end of 2024. The early-stage study has an estimated enrollment of six patients and a primary completion date set for March 2025.
Carisma believes CT-0525 will build on the clinical anti-tumor activity observed with CT-0508 while allowing for significant dose escalation, improved tumor infiltration, increased persistence and reduced manufacturing time compared to CT-0508.
Other prioritized pipeline programs include an in vivo CAR-M pact with Moderna. In 2022, the Big Biotech paid out $45 million in cash to work with Carisma on redirecting endogenous myeloid cells against tumor-associated antigens using mRNA/LNP.
The prioritized programs demonstrate the greatest overall potential and near-term milestones, Carisma CEO Steven Kelly said in the April 1 release.
The Philadelphia-based biotech is also pausing development of CT-1119, a preclinical anti-mesothelin CAR-monocyte, pending additional financing, according to the release.
As of Dec. 31, 2023, Carisma had $77.6 million on hand, cash that is expected to fund the biotech after restructuring efforts take effect into the third quarter of 2025.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.